KR20120103557A - 파킨슨씨병 치료용 조성물 및 치료방법 - Google Patents

파킨슨씨병 치료용 조성물 및 치료방법 Download PDF

Info

Publication number
KR20120103557A
KR20120103557A KR1020127005095A KR20127005095A KR20120103557A KR 20120103557 A KR20120103557 A KR 20120103557A KR 1020127005095 A KR1020127005095 A KR 1020127005095A KR 20127005095 A KR20127005095 A KR 20127005095A KR 20120103557 A KR20120103557 A KR 20120103557A
Authority
KR
South Korea
Prior art keywords
dopamine
receptor
days
disease
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127005095A
Other languages
English (en)
Korean (ko)
Inventor
필립 시맨
Original Assignee
클레라 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클레라 아이엔씨. filed Critical 클레라 아이엔씨.
Publication of KR20120103557A publication Critical patent/KR20120103557A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127005095A 2009-07-31 2010-07-30 파킨슨씨병 치료용 조성물 및 치료방법 Ceased KR20120103557A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23026409P 2009-07-31 2009-07-31
US61/230,264 2009-07-31

Publications (1)

Publication Number Publication Date
KR20120103557A true KR20120103557A (ko) 2012-09-19

Family

ID=43528672

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005095A Ceased KR20120103557A (ko) 2009-07-31 2010-07-30 파킨슨씨병 치료용 조성물 및 치료방법

Country Status (12)

Country Link
US (1) US9192605B2 (enExample)
EP (1) EP2459194A4 (enExample)
JP (1) JP5756105B2 (enExample)
KR (1) KR20120103557A (enExample)
CN (1) CN102548555A (enExample)
AU (1) AU2010278645A1 (enExample)
BR (1) BR112012008193A2 (enExample)
CA (1) CA2769149A1 (enExample)
IL (1) IL217149A0 (enExample)
MX (1) MX2012001290A (enExample)
NZ (1) NZ598247A (enExample)
WO (1) WO2011011886A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3178035A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
JP6371716B2 (ja) * 2014-04-01 2018-08-08 東京エレクトロン株式会社 基板液処理装置及び基板液処理方法並びに基板液処理プログラムを記録したコンピュータ読み取り可能な記録媒体
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN114601928B (zh) * 2022-04-02 2023-03-17 首都医科大学 一种钙超载介导神经元死亡的标志物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма
US20010056101A1 (en) * 1998-06-29 2001-12-27 Carol A. Tamminga Use of dopamine receptor antagonists in combination with partial dopamine agonist to prevent tolerance in treating nervous disorders related to dopamine dysfunction
DE10111486A1 (de) * 2001-03-09 2002-10-02 Ralph R Dawirs Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit
ES2286453T3 (es) * 2002-09-17 2007-12-01 Motac Neuroscience Limited Tratamiento de la discinesia.
CN1802153A (zh) * 2002-10-22 2006-07-12 药物滥用科学研究公司 用选择性多巴胺d1受体激动剂治疗认知损害
CA2628298A1 (en) * 2004-11-03 2006-05-11 Clera Inc. Method to detect dopamine receptors in the functional d2high state
AU2009212065B2 (en) * 2008-02-05 2014-03-20 Clera Inc. Compositions and methods for alleviating depression or improving cognition

Also Published As

Publication number Publication date
CA2769149A1 (en) 2011-02-03
US9192605B2 (en) 2015-11-24
EP2459194A4 (en) 2012-12-19
JP2013500943A (ja) 2013-01-10
IL217149A0 (en) 2012-02-29
AU2010278645A1 (en) 2012-03-08
CN102548555A (zh) 2012-07-04
US20120115910A1 (en) 2012-05-10
JP5756105B2 (ja) 2015-07-29
BR112012008193A2 (pt) 2016-03-01
NZ598247A (en) 2014-01-31
MX2012001290A (es) 2012-06-12
WO2011011886A1 (en) 2011-02-03
EP2459194A1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
AU2002351381B2 (en) Method for treating circadian rhythm disruptions
CA2451566C (en) Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury
JP2003525903A (ja) コリンエステラーゼ阻害剤の新規使用法
WO2005055951A2 (en) Methods and compositions for slowing aging
TW200936127A (en) Use of cannabinoids in combination with an anti-psychotic medicament
JP6762312B2 (ja) 過剰な体脂肪の治療処置または美容処置のためのｎｋ−３受容体拮抗薬
CA2585536A1 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
JP2013056911A (ja) 運動障害の予防および／または治療剤
AU2002328837A1 (en) Use of NK-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
CN102695502A (zh) 用于治疗药瘾和改善药瘾相关行为的组合物
JP2008519847A (ja) 運動障害の治療方法
US20130150434A1 (en) Methods of using low-dose doxepin for the improvement of sleep
KR20120103557A (ko) 파킨슨씨병 치료용 조성물 및 치료방법
TW202245765A (zh) 運動障礙
MX2007006825A (es) Agente preventivo o terapeutico para trastorno del sueno.
CN107961215A (zh) 一种左西替利嗪注射剂
EP2744497B1 (en) Therapeutic combinations of netupitant and palonosetron
MXPA06006685A (es) Uso de gaboxadol para tratar el insomnio.
EP3369422A1 (en) External preparation
WO2006009093A1 (ja) 睡眠障害の予防および／または治療剤
ES2289494T3 (es) Utilizacion de derivados de piridin-2-il-metilamina para el tratamiento de los sintomas del dolor cronico de origen neuropatico o psicogeno.
US20230301985A1 (en) Movement disorders
WO2025236000A1 (en) Use of adamantane compositions and methods of reducing fibrotic tissue
HK1172275A (en) Compositions and methods for treating parkinson's disease
HK1194977B (en) Therapeutic combinations of netupitant and palonosetron

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150728

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160810

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161024

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160810

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I